Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma - Moderna Investor Relations

Submitted by modernatxcom6134 on December 15, 2023 at 11:34 AM in news

mRESVIA is Moderna's second approved product and the only RSV vaccine available in single

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non

Search